LMR Partners’s Kyverna Therapeutics KYTX Stock Holding History

LMR Partners’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-104,814	Closed	-$2.6M	–	1346
2024 Q1	$2.6M	Buy	+104,814	New	+$2.92M	0.03%	490

Other funds holding KYTX

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LMR Partners's KYTX Position: Q2 2024 in Review

LMR Partners sold out of Kyverna Therapeutics (KYTX) in Q2 2024, closing a stake of 104,814 shares — an estimated $2.6M sold.

LMR Partners first reported a position in KYTX in Q1 2024 and held it in 1 quarter. The position peaked at $2.6M in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q2 2024.

LMR Partners reported no remaining Kyverna Therapeutics position as of Q2 2024 after selling out during the quarter.
LMR Partners sold 104,814 Kyverna Therapeutics shares in Q2 2024, an estimated $2.6M.
LMR Partners first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 1 quarter.
LMR Partners's Kyverna Therapeutics position peaked at $2.6M in Q1 2024.
88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.